論文 2024年

2024年

英文

  1. Shiomi I, Makuuchi Y, Noura I, Kakuno S, Niki M, Kaimi Y, Ido K, Sakatoku K, Kuno M, Takakuwa T, Okamura H, NishiInvasivemoto M, NakashimaY, Nakamae M, Kakeya H, Kohashi K, Hino M, Nakamae H. Fungal infection caused by Blastobotrys mokoenaii in an immunocompromised patient with acute myeloid leukemia: A case report. J Infect Chemother. 2024;Jun30(6):557-561. doi.org/10.1016/j.jiac.2023.12.002
  2. Kobayashi K, Hata A, Imoto W, Kakuno S, Shibata W, Yamada K, Kawaguchi H, Sakurai N, Ito T, Uenoyama K, Takahashi T, Ueda S, Katayama T, Onoue M, Kakeya H. Evaluation of predictors of third-generation cephalosporin non-susceptibility and factors affecting recurrence or death in bacteremia caused by Citrobacter freundii complex , Enterobacter cloacae complex, and Klebsiella aerogenes. J Chemother. 2024 Mar 7:1-11. doi: 10.1080/1120009X.2024.2323326. Online ahead of print.
  3. Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, Kaku N, Matsumoto K, Suita A, Mukai E, Nitahara Y, Konishi A, Kasamatsu A, Nakagama S, Nakagami-Yamaguchi E, Ohfuji S, Kaneko Y, Kaneko A, Kakeya H, Hirota Y. Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses. Sci Rep. 2024 Mar 27;14(1):7217. doi: 10.1038/s41598-024-57931-0.
  4. Imoto W, Ihara Y, Imai T, Tamato M, Ibuki T, Yamada K, Kaneko Y, Shintani A, Kakeya H. Evaluating the association of body mass index with COVID-19 severity and mortality using Japanese administrative claims data. J Infect Chemother, 2024 Apr 16:S1341-321X(24)00115-6. doi: 10.1016/j.jiac.2024.04.007. Online ahead of print.
  5. Kakeya H. Exploratory research for new diagnostic markers of mucormycosis. Med Mycol J, 65(2):29-32, 2024
  6. Yamada K, Kakeya H. Status and challenge of antifungal stewardship at the Osaka Metropolitan University Hospital. Med Mycol J, 65(2):33-38, 2024
  7. Imoto W, Ihara Y, Imai T, Tamoto M, Ibuki T, Yamada K, Kaneko Y, Shintani A, Kakeya H. Evaluating the association of body mass index with COVID-19 severity and mortality using Japanese administrative claims data. J Infect Chemother. 2024 Apr 16:S1341-321X(24)00115-6. doi: 10.1016/j.jiac.2024.04.007. Online ahead of print.
  8. Imoto W, Imai T, Kawai R, Ihara Y, Nonomiya Y, Namikawa H, Yamada K, Yoshida H, Kaneko Y, Shintani A, Kakeya H. Incidence and Potential Risk Factors of Human Cytomegalovirus Infection in Patients with Severe and Critical Coronavirus disease 2019. J Infect Chemother . 2024 Jun 27:S1341-321X(24)00171-5. doi: 10.1016/j.jiac.2024.06.015. Online ahead of print.

和文

  1. 掛屋　弘. 予防接種の安全性と有効性. 今日の治療指針2024. 医学書院 2024, pp229-232.
  2. 掛屋 弘. 新型コロナのパンデミックを経験して〜これからの感染症研究への期待〜. バムサジャーナル, 36(2):3-11, 2024
  3. 柴多 渉, 掛屋 弘. ムーコル. 医学の歩み, 289(6):462-466, 2024
  4. 岡田恵代, 野々瀬由佳, 藤田明子, 櫻井紀宏, 中家清隆, 山田康一, 掛屋 弘. 蛍光塗料塗布面積解析ツールを用いた手指衛生手技の教育効果の検討 . 日本環境感染学会誌. 39(3) :70-75, 2024
  5. 掛屋 弘. 院内肺炎診療におけるタゾバクタム・セフトロザン（TAZ/CTLZ）の位置付け. 緑膿菌研究会会誌, 17-22, 2024
  6. 掛屋 弘.抗菌薬使用最適化をめざした地域連携活動. 緑膿菌研究会会誌, 47-52, 2024
論文バックナンバーに戻る
論文 2023年